SpyGlass Pharma Inc banner

Intrinsic Value

The intrinsic value of SpyGlass Pharma Inc (SGP) under the Base Case is 1.21 USD per share. Compared with the current market price of 32.88 USD, the stock appears Overvalued by 96% .

The intrinsic value is calculated using the DCF method.

Do our valuations actually work? See backtest results .

SGP Intrinsic Value
$1.21
Overvaluation 96%
Intrinsic Value
Price $32.88
Alert me when SGP is below its intrinsic value
Today $0.97 · 97.1% below the current price

We don’t have enough historical valuation data to make this comparison.

Alternatives to SGP

Fundamental Analysis

What SpyGlass Pharma Does

Pharmaceuticals Health Care

SpyGlass Pharma develops eye-treatment products that are designed to deliver medicine inside the eye over a long period of time. Its core idea is to replace frequent eye drops with a small implant or drug-delivery device that an ophthalmologist can place during a routine eye procedure, especially for people being treated for glaucoma or eye pressure control.

Headquarters
United States of America US
Employees
65
IPO date
Feb 6, 2026
Read the full company overview
View Company Overview
Financials

Revenue & Expenses Breakdown
SpyGlass Pharma Inc

Efficiency

Earnings Waterfall
SpyGlass Pharma Inc

Wall St Price Targets

Shareholder Returns

Competitive Landscape

Continue SGP Research

Decided on SpyGlass Pharma? Get an email when SGP reaches the price you’d buy at. Free with an account.

What is the Intrinsic Value of one SGP stock?

The intrinsic value for SpyGlass Pharma Inc (SGP) under the Base Case is 1.21 USD.

Is SGP stock undervalued or overvalued?

Compared with the current market price of 32.88 USD, the stock appears Overvalued by 96% .

How reliable are our estimates? See how past valuations played out
Back to Top